Tejas Desai continues to step up to summarize our journal clubs.
When we do a kidney stone paper this will be the image.
Gorgeous.
Early analytics from #NephJC number 5: POSEIDON
We just finished the latest NephJC and it was awesome. We had the most people and the most tweets we have ever had in a one hour TweetChat. A big thanks to everybody that participated.
Our pipeline of upcoming article is getting a little thin
Please send your suggestions for future NephJCs to NephrologyJC@gmail.com
Hyponatremia Comment up on Pubmed Commons
The wrap up post of the hyponatremia guideline discussion is posted as a comment on all three versions of the guidelines on Pubmed here.
Next #NephJC is POSEIDAN from the Lancet
This study dropped a couple of weeks ago and we pushed up the list to go next week on NephJC.
Look for a full introduction on the NephJC home page in the next couple of days.
Programming Note: due to the fact that I want to remain married, we will be changing the date of the next #NephJC from Tuesday to Wednesday June 25th due to my 14th wedding anniversary.
Hangout #3 is in the can
We had a great discussion tonight with Joel and Swapnil being joined by the Dean of Sodium, Dr. Richard Sterns of the University of Rochester and Dr. Hatim Hassam of the University of Chicago. Check it out.
This is a follow up discussion from our Tweet Chat on June 10. Selected panelists will continue the conversation on the clinical practice guideline on diagnosis and treatment of hyponatraemia. This might be the first non-traditional subject for a journal club but it will not be the last.
Edgar Lerma, we like your Twitter style
Marco can finally drink coffee thanks to his new #NephJC mug
Marco won our contest by signing up for the NephJC Newsletter. We expect nephrology efficiency in Bogota to sky rocket.
Though there are no mugs on the line, please sign up for our newsletter so you don't miss any NephJC activities.
NephonDemand Storifies the entire Hyponatremia discussion
He does a nice job editing the discussion from 270 tweets to a bare minimum 54.
First Storify from the Hyponatremia #NephJC
We had a number topics in the discussion but one of the best ones was the discussion surrounding the recommendation against using Vaptans in hyponatremia. Here is the Storify:
NephJC #4 is a wrap. Check out the analytics and transcript
A lot of new faces out there for the NephJC. We had a spirited discussion on hyponatremia. Though the live chat is over we will be monitoring the #NephJC hashtag for the next few days.
Look for more coverage of the Hyponatremia Clinical Practice Guidelines to come.
When Dr. Goldfarb complains he gets results
We received his tweet
We replied with some snark
But then we fixed the page on the website.
Old website implying that hyponatremia is a sodium problem...
...but any nephrologist worth his salt will tell you that hyponatremia is a water problem.
Michael Katz killing it with alternative hyponatremia flow charts
Goldfarb throws in his 2 cents on mild chronic hyponatremia
Goldfarb claims that arthropods can do science. I'll believe it when I see it.
Pubmed reference here.
The Good, the Bad, and the Ugly. Over and over again.
and I bet every author thought they were being hip and original.
SYMPLICITY HTN-3 is now up on PubMed Commons
Swapnil brought our SYMPLICITY coverage to PubMed, check it out.
And the winner is...
Last week we announced a contest to win a NephJC coffee mug
We had a surge of new people sign up for the newsletter and we have randomly selected a winner from this cohort.
Marco Anaya Taboada of Bogota Columbia has won a NephJC mug. Now I just need to figure out how to ship one to South America.
Congratulations Marco!
Sign up for the NephJC Newsletter by going here.
SYMPLICITY HTN-3 Google Hangout
We were honored to have study author and Hypertension Demi-God, George Bakris join us to discuss the SYMPLICITY trial.
We were also joined by John Mandrola, Matt Sparks, Swapnil Hiremath and Joel Topf.
#NephJC Hangout for SYMPLICITY HTN-3
We will take to the airwaves again to do our best Matt Lauer impressions tomorrow at 9 eastern. Be there or be somewhere else. (We need a better tag line)